Chemoradiotherapy-resistant leukemias often express resistance genes which reduce clinical results from available cytotoxic agents. Clinical modulation of resistance gene products has been hampered by limited efficacy and normal tissue toxicities. Targeted polypeptide toxins which bind to defined receptors on neoplastic blasts and catalytically inactivate protein synthesis may provide a more specific and effective method of altering the apoptotic threshold of cells to cytotoxic drugs and radiation. The applicants have genetically engineered two ricin fusion proteins--GM-CSF-triple-site mutant RTB-RTA and GCSF-triple-site mutant RTB-RTA and tested a diphtheria toxin fusion protein--DTGMCSF and have demonstrated selective cytotoxicity to leukemic blasts for the GMCSF fusion toxins. The applicants propose to investigate the in vitro and in vivo efficacy of these reagents on altering the apoptopic threshold of drug resistant cells and to explore the molecular mechanism for synergy both in cell lines and fresh malignant cells.
Specific Aim 1 tests the ability of fusion toxins to alter the sensitivity of resistant cells to cytotoxic drugs.
Specific Aim 2 evaluates the molecular mechanism for synergy by measuring the intracellular concentrations of resistance gene products and the intracellular distribution of toxin in treated cells.
Specific Aim 3 measures the anti-tumor efficacy of ricin fusion proteins combined with cytotoxic drugs on resistant myeloid leukemias in SCID mice. The results should provide basic scientific information needed to describe the potential of fusion toxins to act as specific drug resistance modulators in therapy of refractory myeloid leukemias.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG2-ET-1 (06))
Program Officer
Wu, Roy S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wake Forest University Health Sciences
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Frankel, Arthur; Liu, Jen-Sing; Rizzieri, David et al. (2008) Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma 49:543-53
Watson, Linley E; Mock, Jonathan; Lal, Hind et al. (2007) Lethal and edema toxins of anthrax induce distinct hemodynamic dysfunction. Front Biosci 12:4670-5
Thorburn, Andrew; Frankel, Arthur E (2006) Apoptosis and anthracycline cardiotoxicity. Mol Cancer Ther 5:197-9
Hogge, Donna E; Yalcintepe, Leman; Wong, Siaw-Hui et al. (2006) Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clin Cancer Res 12:1284-91
Liu, Tie Fu; Hall, Philip D; Cohen, Kimberley A et al. (2005) Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res 11:329-34
Testa, Ugo; Riccioni, Roberta; Biffoni, Mauro et al. (2005) Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood 106:2527-9
Cohen, Kimberley A; Liu, Tie Fu; Cline, J Mark et al. (2005) Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol Immunother 54:799-806
Cohen, Kimberley A; Liu, Tie Fu; Cline, J Mark et al. (2004) Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys. Leuk Lymphoma 45:1647-56
Liu, Tie Fu; Urieto, Jeffrey O; Moore, Joseph E et al. (2004) Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. Exp Hematol 32:277-81
Urieto, Jeffrey O; Liu, TieFu; Black, Jennifer H et al. (2004) Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expr Purif 33:123-33

Showing the most recent 10 out of 31 publications